Pharmaceutical Advancements
-
Eli Lilly’s New Weight-Loss Drug Shows Promising Results; Nvidia Explores New Avenues
Thursday’s market saw oil spike to $119, fueling inflation fears and pushing the S&P 500 below its 200-day moving average. Despite promising diabetes drug data from Eli Lilly, shares remained subdued, awaiting a more impactful GLP-1 oral pill. Nvidia’s AI dominance relies on ecosystem health, with suppliers like Sandisk acting as key indicators for data center demand. Investors navigate these complex trends, with healthcare stocks offering a defensive, albeit challenging, play.
